MPLT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
MapLight Therapeutics Inc (MPLT) does not present a compelling buy opportunity at the moment for a beginner investor with a long-term strategy. While there is some upside potential based on analyst ratings and insider buying, the lack of significant financial growth, neutral trading sentiment, and absence of strong proprietary trading signals suggest holding off for now.
The technical indicators are mixed. The MACD is positive but contracting, RSI is neutral at 42.49, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the pre-market price of $17.42 is below the pivot level of $18.247, indicating potential resistance ahead.
Analyst Stifel has a Buy rating with a $28 price target, suggesting significant upside potential.
Insider George Pavlov purchased 25,000 shares at $17.65, indicating confidence in the stock.
The continuation of the ADEPT-2 study in Alzheimer's disease psychosis is seen as a positive development for the company.
Financial performance is weak, with no revenue and negative net income and EPS.
Trading sentiment from hedge funds and insiders is neutral, with no significant trends.
The stock traded down 1.4% recently, reflecting some negative short-term sentiment.
The company's financials for Q2 2024 show no revenue growth (0% YoY), a net income of -$18.4M, and an EPS of -1.26. Gross margin remains at 0, indicating no profitability.
Stifel analyst Paul Matteis has a Buy rating with a $28 price target, citing potential upside due to the company's muscarinic drug and undervalued current valuation. However, there are lingering questions about the ADEPT-2 study.
